TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04436952

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H7 coil
Description: The H7 coil arm will receive a medial prefrontal cortex (mPFC) DTMS 5 days a week for 8 consecutive weeks = 40 Sessions 20 Hz at 100% MT, 2 s on 20 s off intertrain interval, 50 trains, 2000 stimuli per session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H7 coil
Description: The H7 coil arm will receive a medial prefrontal cortex (mPFC) DTMS 5 days a week for 8 consecutive weeks = 40 Sessions 20 Hz at 100% MT, 2 s on 20 s off intertrain interval, 50 trains, 2000 stimuli per session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cool D-B80
Description: The Cool D-B80 arm will receive dorsomedial prefrontal cortex (DMPFC) rTMS 5 days a week for 8 consecutive weeks = 40 sessions 10 Hz at 120% MT, 5 s on 10 s off intertrain interval, 60 trains, First 3000 pulses to the left DMPFC then 3000 pulses to the right DMPFC. TMS will be done at active state by provocation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cool D-B80
Description: The Cool D-B80 arm will receive dorsomedial prefrontal cortex (DMPFC) rTMS 5 days a week for 8 consecutive weeks = 40 sessions 10 Hz at 120% MT, 5 s on 10 s off intertrain interval, 60 trains, First 3000 pulses to the left DMPFC then 3000 pulses to the right DMPFC. TMS will be done at active state by provocation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Response Prevention (ERP)
Description: The ERP will be conducted for 2 hours on week 1 and week 8 and for 1 hour on Weeks 2 to 7 for a total of 10 hours

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Response Prevention (ERP)
Description: The ERP will be conducted for 2 hours on week 1 and week 8 and for 1 hour on Weeks 2 to 7 for a total of 10 hours

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Response Prevention (ERP)
Description: The ERP will be conducted for 2 hours on week 1 and week 8 and for 1 hour on Weeks 2 to 7 for a total of 10 hours
Study: NCT03203096

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Magnesium citrate / Magnesium oxide

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04477096

Intervention type: DRUG
Group type: OTHER
Intervention: HS-10234
Description: HS-10234

Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine
Description: Emtricitabine
Study: NCT01838096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THA using 4th generation CoC
Study: NCT04198688

Intervention type: BEHAVIORAL
Intervention: Intensive Smoking Cessation Intervention
Description: The intervention comprises 5-6 meetings during six weeks, and can be held in group or as an individual intervention. It is based on counselling and a clearly structured manual-based patient education programme taught by specially trained staff, and contains individual counselling on nicotine replacement therapy or other medical support, according to the level of dependence measured by the Fagerström test score. The first two weeks cover teaching sessions on: ambivalence and motivation, pros and cons of continuous smoking versus cessation, and a quit date is set between the 2. and 3. week. The last 3 sessions cover: risk situations, withdrawal symptoms and medical support for withdrawal symptoms, relapse prevention and how to handle a completely smoke-free life.

Intervention type: BEHAVIORAL
Intervention: Intensive Smoking Cessation Intervention
Description: The intervention comprises 5-6 meetings during six weeks, and can be held in group or as an individual intervention. It is based on counselling and a clearly structured manual-based patient education programme taught by specially trained staff, and contains individual counselling on nicotine replacement therapy or other medical support, according to the level of dependence measured by the Fagerström test score. The first two weeks cover teaching sessions on: ambivalence and motivation, pros and cons of continuous smoking versus cessation, and a quit date is set between the 2. and 3. week. The last 3 sessions cover: risk situations, withdrawal symptoms and medical support for withdrawal symptoms, relapse prevention and how to handle a completely smoke-free life.
Study: NCT02952820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lemborexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lemborexant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04193488

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MTP block
Description: In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasagital scan, the block needle (50 mm 22 Gauge) will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Block group
Description: No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
Study: NCT04692415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degludec
Description: treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
Study: NCT00986765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovenox® (enoxaparin)
Description: Injectable solution 4000 UI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspegic ® (Aspirin)
Description: 100 mg/day
Study: NCT02382536

Intervention type: DEVICE
Intervention: BD Scarlett Infusion set
Description: Each subject will receive subcutaneous infusion from two investigational BD Scarlet infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.

Intervention type: DEVICE
Intervention: Medtronic QuickSet Infusion Set
Description: Each subject will receive subcutaneous infusion from two Medtronic infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
Study: NCT03486834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160
Description: V160 was administered as a 0.5 mL (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant \[MAPA\], 4°C stable formulation) IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160
Description: V160 was administered as a 0.5 mL (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant \[MAPA\], 4°C stable formulation) IM injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution administered as a 0.5 mL IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution administered as a 0.5 mL IM injection
Study: NCT04476797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 +SBRT
Description: 15 minute IV Infusion prior to SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 +SBRT
Description: 15 minute IV Infusion prior to SBRT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo +SBRT
Description: 15 minute IV infusion prior to SBRT
Study: NCT04692415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine U300
Description: treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
Study: NCT03253965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metronome Normal
Description: Steps are timed with the beat of the metronome set to the subject's cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metronome Normal
Description: Steps are timed with the beat of the metronome set to the subject's cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metronome Slow
Description: Steps are timed with the beat of the metronome set to 85% of the subject's cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metronome Slow
Description: Steps are timed with the beat of the metronome set to 85% of the subject's cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metronome Fast
Description: Steps are timed with the beat of the metronome set to 115% of the subject's cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metronome Fast
Description: Steps are timed with the beat of the metronome set to 115% of the subject's cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Normal
Description: Steps are timed with the beat of the music by a rhythm consistent with the subject's cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Normal
Description: Steps are timed with the beat of the music by a rhythm consistent with the subject's cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Slow
Description: Steps are timed with the beat of the music by a rhythm consistent with 85% of the subject's cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Slow
Description: Steps are timed with the beat of the music by a rhythm consistent with 85% of the subject's cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Fast
Description: Steps are timed with the beat of the music by a rhythm consistent with 115% of the subject's cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Fast
Description: Steps are timed with the beat of the music by a rhythm consistent with 115% of the subject's cadence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Auditory cueing
Description: Steps are not timed with any auditory cue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Auditory cueing
Description: Steps are not timed with any auditory cue.
Study: NCT03226236

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: boost radiotherapy (XRT)
Description: Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of vaccine+IL-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous DC vaccine
Description: The first dose (7 to 14 x 10_6 total dendritic cells) will be performed with freshly prepared vaccine, 9 days after leukapheresis; on day +1 starting from cycle 2 (3 weeks after the first cycle, on completion of QA assessments on the cryopreserved products), 5 additional doses will be administered every 3 weeks until maximum six vaccines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose IL-2
Description: high dose IL-2: 18 MIU/m2/day in 500cc administered by continuous IV infusion for 72 hours starting day +2.
Study: NCT02873416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Precision Cells
Description: Precision Cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study: NCT03192735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ApatinibMesylateTablets
Description: Subject will be given ApatinibMesylateTablets 500mg/per day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 /per day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
Study: NCT03937934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Weekly box of healthy groceries and nutrition education including a recipe, food to make the recipe, extra fruit and vegetables.
Study: NCT03041181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360 mg IV Day 1 of each cycle (21 days = 1 cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)
Study: NCT02706912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOTA Therapy
Description: During sessions of approximately one hour in duration, participants practice performing virtual activities of daily living (ADLs) using the VOTA system. During this practice, the participant's real-world motion is replicated by an avatar's motion in the virtual world. To complete the activities, participant's must perform a wide range of functional arm movements while interacting with virtual objects. Individuals are asked to perform three such one-hour virtual ADL practice sessions per week over a participation period of approximately eight weeks.
Study: NCT02973074

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: OLEOvital
Description: 2sachets with 30mg iron per day for a 4 weeks period
Study: NCT02566265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care/Placebo
Study: NCT03041181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
Study: NCT04316013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Inhaled anaesthetic used for maintenance of anaesthesia, dosed as per standard practice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Inhaled anaesthetic used for maintenance of anaesthesia, dosed as per standard practice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous anaesthetic used for induction and maintenance of anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous anaesthetic used for induction and maintenance of anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: 1.5mg/kg loading dose over 20 minutes, followed by an infusion of 2mg/kg/hr up to 4 hours and 1.5mg/kg/hour thereafter. Bolus and maintenance dosages of lidocaine will be per actual body weight and capped at a maximum of 100 kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: 1.5mg/kg loading dose over 20 minutes, followed by an infusion of 2mg/kg/hr up to 4 hours and 1.5mg/kg/hour thereafter. Bolus and maintenance dosages of lidocaine will be per actual body weight and capped at a maximum of 100 kg.
Study: NCT04404491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procedural death 1
Description: 200mg,d1,15,29,43,57,I.V

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo: 200mg,d1,15,29,43,57,I.V
Study: NCT03197896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Review prostate cancer information

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Review prostate cancer information
Study: NCT02899468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrightBrainer Virtual Reality (BBVR) Rehabilitation System
Description: During the active treatment stage (3 sessions per week x 6 weeks), each BBVR therapy session will consist of a series of custom games targeting one or several cognitive domains of executive function, attention, short-term memory, working memory and language comprehension. In addition, the BBVR device incorporates uni- and bi-manual activities by having the subject manipulate hand-held devices, which are programmed to measure in real time the subject's 3D hand movement and index flexion/extension. Therefore, in addition to completing the cognitive tasks, subjects must manipulate virtual hands through a hand-held interface to also enhance visual-motor perception, hand-eye coordination, and upper limb function. In addition, wrist weights can be added to increase upper limb strength training.

Intervention type: DEVICE
Group type: OTHER
Intervention: BrightBrainer Virtual Reality (BBVR) Rehabilitation System
Description: During the active treatment stage (3 sessions per week x 6 weeks), each BBVR therapy session will consist of a series of custom games targeting one or several cognitive domains of executive function, attention, short-term memory, working memory and language comprehension. In addition, the BBVR device incorporates uni- and bi-manual activities by having the subject manipulate hand-held devices, which are programmed to measure in real time the subject's 3D hand movement and index flexion/extension. Therefore, in addition to completing the cognitive tasks, subjects must manipulate virtual hands through a hand-held interface to also enhance visual-motor perception, hand-eye coordination, and upper limb function. In addition, wrist weights can be added to increase upper limb strength training.
Study: NCT00684931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: neuropsychological evaluation and Imaging with magnetic resonance (MRI)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Imaging
Description: neuropsychological evaluation and Imaging with magnetic resonance (MRI)
Study: NCT00960999

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single-fraction stereotactic body radiation therapy (SBRT)
Description: 34 Gy in 1 fraction to the prescription line at the edge of the planning target volume (PTV). The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and \< 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least \< 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be \< 10%.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multiple-fraction stereotactic body radiation therapy (SBRT)
Description: 48 Gy in four 12 Gy fractions to the prescription line at the edge of the planning target volume (PTV). Treatments are given on 4 consecutive calendar days, but at least 18 hours apart. The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and \< 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least \< 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be \< 10%.
Study: NCT02497352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle modification
Study: NCT00327600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imexon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC
Study: NCT03333278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Ascorbic acid 1.5g every 6 hours i.v. while in ICU, until shock resolution for a maximum of ten days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine
Description: Thiamine 200mg every 12 hours i.v. while in ICU, until shock resolution for a maximum of ten days

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone,
Description: Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone,
Description: Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.
Study: NCT04493008

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Experimental: Educational session
Description: Each patient will receive educational session consisting of face-to-face interview, administration of posters, brochures and pamphlets.